CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ku, D. H.
Right arrow Articles by Baserga, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ku, D. H.
Right arrow Articles by Baserga, R.

Cell Growth & Differentiation, Vol 2, Issue 4 179-186, Copyright © 1991 by American Association of Cancer Research


ARTICLES

A new growth-regulated complementary DNA with the sequence of a putative trans-activating factor

DH Ku, CD Chang, J Koniecki, LA Cannizzaro, L Boghosian-Sell, H Alder and R Baserga
Department of Pathology, Temple University Medical School, Philadelphia, Pennsylvania 19104.

A new complementary DNA (cDNA) clone has been isolated by differential screening of a cDNA library. The cognate RNA of this clone, called SC1, is growth regulated in human, mouse, and hamster cell lines. Its kinetics of growth regulation (time of increase in mRNA levels, sensitivity to cycloheximide, behavior in G1-specific temperature-sensitive mutants) classify the SC1 gene as a late growth-regulated gene, like the histone genes and the genes coding for the proteins of the DNA synthesis apparatus. By run-on assay, there is a modest increase in transcriptional rates after serum stimulation, which is not sufficient to explain the sharp increase in mRNA levels. The SC1 gene localizes to human chromosome 6p21-22. In bacteria, the SC1 cDNA clone makes a protein of Mr 39,000, in agreement with the putative reading frame. The amino acid sequence derived from the cDNA sequence indicates a previously unknown gene with a domain strongly suggestive of a trans-activating domain. The SC1 gene can be considered as coding for a possible new trans-activating factor that could play an important role in the transcription of genes required for the later stages of cell cycle progression.


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
K. A. Krautkramer, A. K. Linnemann, D. A. Fontaine, A. L. Whillock, T. W. Harris, G. J. Schleis, N. A. Truchan, L. Marty-Santos, J. A. Lavine, O. Cleaver, et al.
Tcf19 is a novel islet factor necessary for proliferation and survival in the INS-1 {beta}-cell line
Am J Physiol Endocrinol Metab, September 1, 2013; 305(5): E600 - E610.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. P. Trape, M. L. H. Katayama, R. A. Roela, H. Brentani, G. R. Ravacci, L. de Araujo Lima, and M. M. Brentani
Gene Expression Profile in Response to Doxorubicin-Rapamycin Combined Treatment of HER-2-Overexpressing Human Mammary Epithelial Cell Lines
Mol. Cancer Ther., February 1, 2012; 11(2): 464 - 474.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. Zou, H. Ichikawa, M. L. Blackburn, H.-M. Hu, A. Zielinska-Kwiatkowska, Q. Mei, G. J. Roth, H. A. Chansky, and L. Yang
The Oncogenic TLS-ERG Fusion Protein Exerts Different Effects in Hematopoietic Cells and Fibroblasts
Mol. Cell. Biol., July 15, 2005; 25(14): 6235 - 6246.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1991 by the American Association of Cancer Research.